Molecular Oncology, Год журнала: 2025, Номер unknown
Опубликована: Фев. 26, 2025
Язык: Английский
Genome biology, Год журнала: 2022, Номер 23(1)
Опубликована: Авг. 9, 2022
A fused method using a combination of multi-omics data enables comprehensive study complex biological processes and highlights the interrelationship relevant biomolecules their functions. Driven by high-throughput sequencing technologies, several promising deep learning methods have been proposed for fusing generated from large number samples.
Язык: Английский
Процитировано
75
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(5), С. 3040 - 3040
Опубликована: Март 6, 2024
Glioblastoma multiforme (GBM) is the most common and malignant type of primary brain tumor in adults. Despite important advances understanding molecular pathogenesis biology this past decade, prognosis for GBM patients remains poor. characterized by aggressive biological behavior high degrees inter-tumor intra-tumor heterogeneity. Increased cellular heterogeneity may not only help more accurately define specific subgroups precise diagnosis but also lay groundwork successful implementation targeted therapy. Herein, we systematically review key achievements pathogenesis, mechanisms, biomarkers decade. We discuss pathology GBM, including genetics, epigenetics, transcriptomics, signaling pathways. that have potential clinical roles. Finally, new strategies, current challenges, future directions discovering therapeutic targets will be discussed.
Язык: Английский
Процитировано
30
Frontiers in Oncology, Год журнала: 2022, Номер 12
Опубликована: Июнь 29, 2022
Characterization of the tumor microenvironment through immunoprofiling has become an essential resource for understanding complex immune cell interactions and assessment biomarkers prognosis prediction immunotherapy response; however, these studies are often limited by tissue heterogeneity sample size. The nanoString GeoMx ® Digital Spatial Profiler (DSP) is a platform that allows high-plex profiling at protein RNA level, providing spatial temporal tumors in frozen or formalin-fixed paraffin-embedded sample. Recently, high-impact have shown feasibility using this technology to identify different settings, including predictive types. These showed compared other multiplex platforms, DSP can interrogate higher number with throughput; it does not provide single-cell resolution, co-expression biomarker information level. In review, we will describe technical overview platform, present current evidence advantages limitations applications technology, important considerations experimental design translational immune-oncology research tissue-based approach.
Язык: Английский
Процитировано
67
Cancers, Год журнала: 2023, Номер 15(13), С. 3458 - 3458
Опубликована: Июль 1, 2023
Since their discovery at the beginning of this millennium, glioma stem cells (GSCs) have sparked extensive research and an energetic scientific debate about contribution to glioblastoma (GBM) initiation, progression, relapse, resistance. Different molecular subtypes GBM coexist within same tumor, they display differential sensitivity chemotherapy. GSCs contribute tumor heterogeneity recapitulate pathway alterations described for three found in patients. show a high degree plasticity, allowing interconversion between different subtypes, with distinct proliferative potential, degrees self-renewal differentiation. This plasticity permits adaptation environmental changes introduced by chemo- radiation therapy. Evidence from mouse models indicates that repopulate brain tumors after therapeutic intervention, due GSC reconstitute recurrent tumors. are also inherently resilient standard-of-care therapy, mechanisms resistance include enhanced DNA damage repair, MGMT promoter demethylation, autophagy, impaired induction apoptosis, metabolic adaptation, chemoresistance, immune evasion. The remarkable oncogenic properties inspired considerable interest better understanding biology functions, as might represent attractive targets advance currently limited options has raised expectations development novel targeted approaches, including targeting chimeric antigen receptor T (CAR T) cells, oncolytic viruses. In review, we focus on role drivers therapy resistance, discuss how insights into GSC-directed curative approaches.
Язык: Английский
Процитировано
36
Journal of Controlled Release, Год журнала: 2023, Номер 358, С. 98 - 115
Опубликована: Апрель 29, 2023
Glioblastoma (GBM) is an adult's most aggressive brain tumor. The advances in molecular pathology and cell signaling pathways have deepened researchers' understanding of intercellular communication mechanisms that can induce tumor progression, namely the release extracellular vesicles. Exosomes are small vesicles various biological fluids released by almost all cells, thus carrying biomolecules specific to their parental cell. Several pieces evidence indicate exosomes mediate microenvironment cross blood-brain barrier (BBB), valuable tools for diagnostic therapeutic applications under scope diseases such as tumors. This review aims resume several characteristics interplay between glioblastoma exosomes, describing highlight studies demonstrate role GBM potential non-invasive diagnoses approaches, namely, nanocarriers drug or gene delivery cancer vaccines.
Язык: Английский
Процитировано
26
Brain Sciences, Год журнала: 2023, Номер 13(11), С. 1602 - 1602
Опубликована: Ноя. 17, 2023
This systematic review assesses current molecular targeted therapies for glioblastoma multiforme (GBM), a challenging condition with limited treatment options. Using PRISMA methodology, 166 eligible studies, involving 2526 patients (61.49% male, 38.51% female, male-to-female ratio of 1.59/1), were analyzed. In laboratory 52.52% primarily used human cell cultures (HCC), and 43.17% employed animal samples (mainly mice). Clinical participants ranged from 18 to 100 years, 60.2% using combined 39.8% monotherapies. Mechanistic categories included Protein Kinase Phosphorylation (41.6%), Cell Cycle-Related Mechanisms (18.1%), Microenvironmental Targets (19.9%), Immunological (4.2%), Other (16.3%). Key targets Epidermal Growth Factor Receptor (EGFR) (10.8%), Mammalian Target Rapamycin (mTOR) (7.2%), Vascular Endothelial (VEGF) (6.6%), Mitogen-Activated (MEK) (5.4%). provides comprehensive assessment GBM, highlighting their varied efficacy in clinical settings, ultimately impacting overall progression-free survival GBM management.
Язык: Английский
Процитировано
22
Pharmaceutics, Год журнала: 2024, Номер 16(1), С. 100 - 100
Опубликована: Янв. 11, 2024
Glioblastoma multiforme (GBM) is the most common type of glioma, with a median survival 14.6 months post-diagnosis. Understanding molecular profile such tumors allowed development specific targeted therapies toward GBM, major role attributed to tyrosine kinase receptor inhibitors and immune checkpoint inhibitors. Targeted therapeutics are drugs that work by binding GBM-specific or overexpressed markers on tumor cellular surface therefore contain recognition moiety linked cytotoxic agent, which produces an antiproliferative effect. In this review, we have summarized available information used in clinical trials GBM current obstacles advances therapy concerning targets present cells, outlined efficacy endpoints for classes investigational drugs, discussed promising strategies towards increase drug GBM.
Язык: Английский
Процитировано
12
ACS Applied Nano Materials, Год журнала: 2024, Номер 7(3), С. 2430 - 2460
Опубликована: Янв. 22, 2024
Malignant glioblastoma, also known as Glioblastoma multiforme (GBM), is one of the most aggressive subtypes, characterized by wide vascularization and complex invasion. The currently available standard care for GBM includes maximal surgical resection, radiotherapy, chemotherapy. These therapeutic procedures are facilitating treatment means prolonging lifetime. However, these processes cannot prevent tumor recurrence in future thereby compromise patient This disease accredited to presence glioma stem cells (GSCs) that resistant toward chemo radiation therapies. GSCs mainly associated with vascular niches control GSC self-renewal survival. Therefore, targeting using various nanoparticle-assisted therapeutics may improve efficacy drugs used alone or combination result progress Nanoparticles have been designed an aim selectively deliver cargo target therefore considerable interest use cancer cell (CSC) directed anticancer structure properties nanomaterials influencing propagation differentiation extensively studied become a cutting-edge research domain material science regenerative medicines. due microenvironment heterogeneity interpatient variability, nanoparticles yielded few clinical outcomes. Despite formidable challenges, nanotechnology presents opportunities can significantly enhance our grasp fate enable development groundbreaking In doing so, nanoparticle-based therapy has risen promising armamentarium make substantial contributions effective glioblastoma.
Язык: Английский
Процитировано
12
Cells, Год журнала: 2024, Номер 13(3), С. 218 - 218
Опубликована: Янв. 25, 2024
Brain tumors represent a heterogeneous group of neoplasms characterized by high degree aggressiveness and poor prognosis. Despite recent therapeutic advances, the treatment brain tumors, including glioblastoma (GBM), an aggressive primary tumor associated with prognosis resistance to therapy, remains significant challenge. Receptor tyrosine kinases (RTKs) are critical during development in adulthood. Dysregulation RTKs through activating mutations gene amplification contributes many human cancers provides attractive targets for treatment. Under physiological conditions, Met RTK, hepatocyte growth factor/scatter factor (HGF/SF) receptor, promotes fundamental signaling cascades that modulate epithelial-to-mesenchymal transition (EMT) involved tissue repair embryogenesis. In cancer, increased activity metastasis providing signals proliferation, survival, migration/invasion. Recent clinical genomic studies have unveiled multiple mechanisms which MET is genetically altered GBM, focal amplification, chromosomal rearrangements generating fusions, splicing variant mutation (exon 14 skipping, METex14del). Notably, overexpression chemotherapy GBM promoting survival cancer stem-like cells. This linked distinctive Met-induced pathways, such as upregulation DNA mechanisms, can protect cells from cytotoxic effects chemotherapy. The MET-targeted therapies represents major step forward tumours. Preclinical shown (monoclonal antibodies or small molecule inhibitors) suppress invasion, enhancing efficacy conventional therapies. Early-phase trials demonstrated promising results improving overall patients recurrent GBM. However, challenges remain, need patient stratification, optimization regimens, identification resistance. review aims highlight current understanding underlying dysregulation addition, it will focus on ongoing preclinical assessment targeting
Язык: Английский
Процитировано
9
Cancer Chemotherapy and Pharmacology, Год журнала: 2024, Номер 93(5), С. 455 - 469
Опубликована: Янв. 27, 2024
Язык: Английский
Процитировано
9